1. Benjamin EJ, Virani SS, Callaway CW, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2018;137:e67–e492.
2. Sato N. Epidemiology of Heart Failure in Asia. Heart Fail Clin 2015;11:573–579.
5. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 2007;115:1563–1570.
7. Go AS, Mozaffarian D, Roger VL, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014;129:e28–e292.
8. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287:628–640.
11. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022;145:e876–e894.
12. Fang JC, Ewald GA, Allen LA, et al.; Heart Failure Society of America Guidelines Committee. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail 2015;21:519–534.
13. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009;28:535–541.
14. van Diepen S, Katz JN, Albert NM, et al.; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017;136:e232–e268.
15. Barge-Caballero E, Segovia-Cubero J, Almenar-Bonet L, et al. Preoperative INTERMACS profiles determine postoperative outcomes in critically ill patients undergoing emergency heart transplantation: analysis of the Spanish National Heart Transplant Registry. Circ Heart Fail 2013;6:763–772.
16. Goldstein DJ, Meyns B, Xie R, et al. Third Annual Report from the ISHLT Mechanically Assisted Circulatory Support Registry: a comparison of centrifugal and axial continuous-flow left ventricular assist devices. J Heart Lung Transplant 2019;38:352–363.
21. Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 2011;39:450–455.
22. Levy B, Clere-Jehl R, Legras A, et al.; Collaborators. Epinephrine Versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 2018;72:173–182.
23. De Backer D, Biston P, Devriendt J, et al.; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779–789.
24. Mathew R, Di Santo P, Jung RG, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med 2021;385:516–525.
26. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009;11:304–311.
27. Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis. Int J Cardiol 2016;202:138–143.
29. Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003;9:180–187.
33. Repasos E, Kaldara E, Ntalianis A, et al. Intermittent renal replacement therapy for end stage drug refractory heart failure. Int J Cardiol 2015;183:24–26.
34. Herweg B, Barold SS. When is it too late for cardiac resynchronization therapy? Pacing Clin Electrophysiol 2008;31:525–528.
35. Bristow MR, Saxon LA, Boehmer J, et al.; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2450.
36. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007;115:204–212.
37. Carluccio E, Biagioli P, Alunni G, et al. Presence of extensive LV remodeling limits the benefits of CRT in patients with intraventricular dyssynchrony. JACC Cardiovasc Imaging 2011;4:1067–1076.
40. Huang W, Zhou X, Ellenbogen KA. Pursue physiological pacing therapy: a better understanding of left bundle branch pacing and left ventricular septal myocardial pacing. Heart Rhythm 2021;18:1290–1291.
41. Curila K, Jurak P, Jastrzebski M, et al. Left bundle branch pacing compared to left ventricular septal myocardial pacing increases interventricular dyssynchrony but accelerates left ventricular lateral wall depolarization. Heart Rhythm 2021;18:1281–1289.
42. Jastrzębski M, Moskal P, Huybrechts W, et al. Left bundle branch-optimized cardiac resynchronization therapy (LOTCRT): Results from an international LBBAP collaborative study group. Heart Rhythm 2022;19:13–21.
43. Moss AJ, Zareba W, Hall WJ, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.
44. Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.
45. Køber L, Thune JJ, Nielsen JC, et al.; DANISH Investigators. Defibrillator Implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221–1230.
46. Packer M, Grayburn PA. New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation. JAMA Cardiol 2020;5:469–475.
47. Gaasch WH, Meyer TE. Secondary mitral regurgitation (part 1): volumetric quantification and analysis. Heart 2018;104:634–638.
49. Bartko PE, Heitzinger G, Arfsten H, et al. Disproportionate functional mitral regurgitation: advancing a conceptual framework to clinical practice. JACC Cardiovasc Imaging 2019;12:2088–2090.
51. Godino C, Munafò A, Scotti A, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. J Heart Lung Transplant 2020;39:1353–1362.
52. Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol 2011;57:688–696.
53. Smedira NG, Moazami N, Golding CM, et al. Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: survival at five years. J Thorac Cardiovasc Surg 2001;122:92–102.
54. Cheng JM, den Uil CA, Hoeks SE, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 2009;30:2102–2108.
55. Alba AC, Rao V, Ivanov J, Ross HJ, Delgado DH. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant 2009;28:827–833.
56. Lima B, Kale P, Gonzalez-Stawinski GV, Kuiper JJ, Carey S, Hall SA. Effectiveness and safety of the impella 5.0 as a bridge to cardiac transplantation or durable left ventricular assist device. Am J Cardiol 2016;117:1622–1628.
57. Kirklin JK, Naftel DC, Kormos RL, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant 2012;31:117–126.
59. Thiele H, Zeymer U, Neumann FJ, et al.; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287–1296.
60. Thiele H, Zeymer U, Neumann FJ, et al.; Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013;382:1638–1645.
61. Sandhu A, McCoy LA, Negi SI, et al. Use of mechanical circulatory support in patients undergoing percutaneous coronary intervention: insights from the National Cardiovascular Data Registry. Circulation 2015;132:1243–1251.
63. Kawashima D, Gojo S, Nishimura T, et al. Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIO J 2011;57:169–176.
64. Koeckert MS, Jorde UP, Naka Y, Moses JW, Takayama H. Impella LP 2.5 for left ventricular unloading during venoarterial extracorporeal membrane oxygenation support. J Card Surg 2011;26:666–668.
65. Rao P, Khalpey Z, Smith R, Burkhoff D, Kociol RD. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. Circ Heart Fail 2018;11:e004905.
66. Biscotti M, Bacchetta M. The “sport model”: extracorporeal membrane oxygenation using the subclavian artery. Ann Thorac Surg 2014;98:1487–1489.
67. Chicotka S, Rosenzweig EB, Brodie D, Bacchetta M. The “Central Sport Model”: extracorporeal membrane oxygenation using the innominate artery for smaller patients as bridge to lung transplantation. ASAIO J 2017;63:e39–e44.
69. Mehra MR, Uriel N, Naka Y, et al.; MOMENTUM 3 Investigators. A fully magnetically levitated left ventricular assist device - final report. N Engl J Med 2019;380:1618–1627.
70. Molina EJ, Shah P, Kiernan MS, et al. The Society of Thoracic Surgeons Intermacs 2020 annual report. Ann Thorac Surg 2021;111:778–792.
71. Slaughter MS, Rogers JG, Milano CA, et al.; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241–2251.
72. Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med 2017;376:451–460.
73. Frazier OH, Rose EA, Oz MC, et al.; HeartMate LVAS Investigators. Left Ventricular Assist System. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001;122:1186–1195.
76. Starling RC, Estep JD, Horstmanshof DA, et al.; ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results. JACC Heart Fail 2017;5:518–527.
80. Yoon M, Oh J, Lee CJ, et al. Impact of predicted heart mass-based size matching on survival after heart transplantation in Korea: Analysis of the Korean Organ Transplant Registry. J Heart Lung Transplant 2022;41:1751–1760.
81. Lee JM, Choi KH, Choi JO, et al. Coronary microcirculatory dysfunction and acute cellular rejection after heart transplantation. Circulation 2021;144:1459–1472.
84. Mehra MR, Canter CE, Hannan MM, et al.; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1–23.
85. Kittleson MM, Patel JK, Kobashigawa JA. Cardiac transplantation. In: Fuster V, Harrington RA, Narula J, Eapen ZJ, eds. Hurst’s The Heart. 14th ed. New York, NY: McGraw-Hill Education, 2017.
86. Wever-Pinzon O, Drakos SG, Fang JC. Team-based care for advanced heart failure. Heart Fail Clin 2015;11:467–477.